
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics is well-positioned in the fast-growing field of allogeneic iNKT cell therapy, which offers distinct advantages over traditional therapies for cancer and other immune-mediated diseases. With a strong pipeline of innovative products, including the promising agenT-797, and a focus on single segment operations, the company has a solid foundation for future success. While additional financing may be needed in the coming years, the company's cash runway into late 2026/early 2027 and strong intellectual property protection provide reassurance for long-term investors.
Bears say
MiNK Therapeutics is facing decreased operating expenses and has a low cash balance, which may hinder its ability to advance its product candidate agenT-797 in its clinical trials. Additionally, the company’s reliance on external funding for its Phase 2 trials may not lead to significant R&D expenses, limiting its ability to effectively develop and bring its product to market. With a lowered discount rate, the company may have more financial flexibility, but the uncertainty surrounding its product and funding sources leads to a negative outlook on its stock.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares